ZIOPHARM Oncology (NASDAQ:ZIOP) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.34), Fidelity Earnings reports.
ZIOP stock traded up $0.17 during trading on Friday, hitting $4.44. 1,347,500 shares of the company traded hands, compared to its average volume of 1,725,203. The stock’s 50-day simple moving average is $4.22 and its 200 day simple moving average is $4.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.33 and a quick ratio of 6.33. The company has a market cap of $794.72 million, a PE ratio of -9.25 and a beta of 2.60. ZIOPHARM Oncology has a 1 year low of $1.56 and a 1 year high of $7.25.
Several research analysts have recently issued reports on the company. HC Wainwright restated a “buy” rating and issued a $6.50 price objective on shares of ZIOPHARM Oncology in a research note on Wednesday, October 2nd. Zacks Investment Research upgraded ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, October 12th. BidaskClub upgraded ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research note on Tuesday, October 29th. Raymond James set a $6.50 price objective on ZIOPHARM Oncology and gave the stock an “outperform” rating in a research note on Friday. Finally, ValuEngine cut ZIOPHARM Oncology from a “sell” rating to a “strong sell” rating in a research note on Wednesday, October 2nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $6.25.
ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.
Recommended Story: Net Margin
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.